Moleculin Biotech completes Part A enrollment in MIRACLE; 89 patients, Q1 2027 readout on track

Moleculin Biotech completed enrollment of 89 subjects in Part A of the pivotal Phase 2/3 MIRACLE trial, keeping a comprehensive Part A data readout on track for Q1 2027.Key Highlights:Original SEC Filing: Moleculin Biotech, Inc. [ MBRX ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It may co…